The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2024

Filed:

Sep. 10, 2021
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Achal Pashine, Mahwah, NJ (US);

Michael L. Gosselin, Boston, MA (US);

Aaron P. Yamniuk, Lawrenceville, NJ (US);

Derek A. Holmes, Lawrenceville, NJ (US);

Guodong Chen, East Brunswick, NJ (US);

Priyanka Apurva Madia, Franklin Park, NJ (US);

Richard Yu-Cheng Huang, Bridgewater, NJ (US);

Stephen Michael Carl, Howell, NJ (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 29/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 47/6803 (2017.08); A61P 29/00 (2018.01); C12N 15/85 (2013.01); C07K 2317/32 (2013.01); C07K 2317/565 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.


Find Patent Forward Citations

Loading…